Results 141 to 150 of about 53,966 (229)

PD‐1/PD‐L1 in Hepatocellular Carcinoma (2014–2024): A Combined Macro and Micro Analysis of Immunotherapy Implications

iNew Medicine, Volume 2, Issue 1, March 2026.
ABSTRACT Hepatocellular carcinoma (HCC) represents a significant global health issue, with the PD‐1/PD‐L1 axis serving a pivotal target for immunotherapy in this malignancy. However, a comprehensive bibliometric analysis of PD‐1/PD‐L1 research in HCC is lacking.
Xingyu Zhu, Lin Tang, Hongyan Li, Hao Li, Jiamei Wang   +4 more
wiley   +1 more source

A machine learning approach to identify optimal candidates for transarterial chemoembolization in unresectable HBV-related hepatocellular carcinoma complicated by first-branch portal vein tumor thrombus: a multicenter study. [PDF]

Front Oncol
Zhao S, Zhang Q, Tang Y, Wang Y, Song J, Han T, Zhao H, Zhang Y, Yuan C, Li X, Zhu J, Zhao L.   +11 more
europepmc   +1 more source

Synthesis, Antitumor Activity Evaluation and Mechanistic Study of Novel Bis‐Heterocyclic Chalcones Against Liver Cancer

Journal of Clinical Laboratory Analysis, Volume 40, Issue 5, March 2026.
Western blotting was performed to analyze the expression of Caspase 3 and Cleaved‐Caspase 3 in Huh1 cells following different treatments, which supports the finding that bis‐heterocyclic chalcones 3d and 3f can inhibit the activity of hepatocellular carcinoma cells by inducing apoptosis.
Zhifen Li, Jingbo Ma, Xiannian Lv, Lei Zhang, Hai Xie   +4 more
wiley   +1 more source

USP20 governs tyrosine kinase inhibitors resistance through ferroptosis evasion by targeting GPX4 in cancers. [PDF]

Redox Biol
Wang Y, Liu B, Zhuang Y, Zhang Y, Dan W, Ding P, Wei Y, Guo C, Li M, Wang C, Baoerbieke Y, Pei X, Li L, Fan Y.   +13 more
europepmc   +1 more source

Endoscopic Innovation Treatment Strategy in Hepatocellular Carcinoma (HCC) Patients Before Immunotherapy: A Case Series Study in Unselected Patients

JGH Open, Volume 10, Issue 3, March 2026.
ABSTRACT Hepatocellular carcinoma remains a major problem in Asia as well as globally. Most patients present at the late stage of the disease. Currently, several types of immunotherapy (IT) have been studied for its efficacy in treating hepatocellular carcinoma, such as atezolizumab and bevacizumab, which work as inhibitors in checkpoints and ...
Stephen Dario Syofyan, Kenoah Kovara, Nicholas Putra Lesmana, Josia Nathanael Wiradikarta, Joshua Francisco Syofyan, Juan Benedict Widjaja, Sri Inggriani, Rio Hermawan, Cosmas Rinaldi Adithya Lesmana   +8 more
wiley   +1 more source

Anlotinib and penpulimab in advanced hepatocellular carcinoma: a new contender emerges. [PDF]

J Gastrointest Oncol
Abidoye O, Ahn D.
europepmc   +1 more source

Artificial intelligence strategies for predicting kinase inhibitor resistance: A comprehensive review of methods, challenges, and future perspectives

Journal of Intelligent Medicine, Volume 3, Issue 1, Page 26-46, March 2026.
Abstract Kinase inhibitors are essential in targeted cancer therapy, yet resistance often emerges through secondary mutations, activation of compensatory signaling pathways, or drug‐efflux mechanisms. Artificial intelligence (AI) provides a workflow‐based strategy rather than a list of unrelated tools for predicting and addressing kinase‐inhibitor ...
Faris Hassan, Mohanad Ali Deifallah, Alaa Zaghloul, Rania Elgohary   +3 more
wiley   +1 more source

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma: A cost-effectiveness analysis. [PDF]

Cancer
Luo J, Li Z, Ge J, Cai S, Mo X, Liu W, Gui C, Du Q, Liu J.   +8 more
europepmc   +1 more source

Chromatin Accessibility in Cancer: Biological Functions, Mechanisms, Therapeutic Potential, and Future Directions

MedComm, Volume 7, Issue 3, March 2026.
Cancer remains the leading cause of mortality worldwide, and drug resistance further underscores the urgent need for innovative therapeutic strategies. Chromatin, a stable yet highly dynamic nucleoprotein complex, serves as the primary carrier of genetic material in eukaryotic cells.
Wentao Xia, Min Jiang, Yefei Huang, Kun Ding, Yansu Chen   +4 more
wiley   +1 more source

Efficacy and safety of first-line immunotherapy and targeted therapy in advanced HCC: a network meta-analysis with subgroup analysis based on HBV and HCV infection. [PDF]

Front Immunol
Li Q, Li H, Ma H, Chen W.
europepmc   +1 more source